Published clinical trials shown to be misleading

Comparison of internal and public reports about Pfizer’s drug Neurontin reveals many discrepancies

Editor’s note: This story was updated on January 31 with comment from Pfizer.

A rare peek into drug company documents reveals troubling differences between publicly available information and materials the company holds close to its chest.